CHMP4C Antikörper (AA 1-233) (HRP)

Produktnummer ABIN7147528

Produktdetails anti-CHMP4C Antikörper (HRP)

Target: CHMP4C (Charged Multivesicular Body Protein 4C (CHMP4C))

Bindungsspezifität: AA 1-233

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser CHMP4C Antikörper ist konjugiert mit HRP

Applikation: ELISA

Kreuzreaktivität: Human

Aufreinigung: >95%, Protein G purified

Immunogen: Recombinant Human Charged multivesicular body protein 4c protein (1-233AA)

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, PH 7.4

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Details zu CHMP4C

Target: CHMP4C (Charged Multivesicular Body Protein 4C (CHMP4C))

Andere Bezeichnung: CHMP4C (CHMP4C Produkte)

Synonyme: 2010012P02Rik antikoerper, 2210015K02Rik antikoerper, 2310010I16Rik antikoerper, Shax3 antikoerper, Snf7-3 antikoerper, SNF7-3 antikoerper, VPS32C antikoerper, zgc:110173 antikoerper, CHMP4c antikoerper, chmp4c antikoerper, charged multivesicular body protein 4C antikoerper, charged multivesicular body protein 4C L homeolog antikoerper, Chmp4c antikoerper, CHMP4C antikoerper, chmp4c antikoerper, chmp4c.L antikoerper

Hintergrund:

Background: Probable core component of the endosomal sorting required for transport complex III (ESCRT-III) which is involved in multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins into MVBs. MVBs contain intraluminal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome and mostly are delivered to lysosomes enabling degradation of membrane proteins, such as stimulated growth factor receptors, lysosomal enzymes and lipids. The MVB pathway appears to require the sequential function of ESCRT-O, -I,-II and -III complexes. ESCRT-III proteins mostly dissociate from the invaginating membrane before the ILV is released. The ESCRT machinery also functions in topologically equivalent membrane fission events, such as the terminal stages of cytokinesis and the budding of enveloped viruses (HIV-1 and other lentiviruses). Key component of the cytokinesis checkpoint, a process required to delay abscission to prevent both premature resolution of intercellular chromosome bridges and accumulation of DNA damage: upon phosphorylation by AURKB, together with ZFYVE19/ANCHR, retains abscission-competent VPS4 (VPS4A and/or VPS4B) at the midbody ring until abscission checkpoint signaling is terminated at late cytokinesis. Deactivation of AURKB results in dephosphorylation of CHMP4C followed by its dissociation from ANCHR and VPS4 and subsequent abscission (PubMed:22422861, PubMed:24814515). ESCRT-III proteins are believed to mediate the necessary vesicle extrusion and/or membrane fission activities, possibly in conjunction with the AAA ATPase VPS4. Involved in HIV-1 p6- and p9-dependent virus release. CHMP4A/B/C are required for the exosomal release of SDCBP, CD63 and syndecan (PubMed:22660413).

Aliases: Charged multivesicular body protein 4c antibody, CHM4C_HUMAN antibody, CHMP4c antibody, Chromatin-modifying protein 4c antibody, hSnf7-3 antibody, hVps32-3 antibody, SHAX3 antibody, SNF7 homolog associated with Alix 3 antibody, SNF7-3 antibody, Vacuolar protein sorting-associated protein 32-3 antibody, Vps32-3 antibody

UniProt: Q96CF2